Nonalcoholic steatohepatitis (NASH) is a progressive liver disease characterized by increased accumulation of fat in hepatocytes in the absence of significant alcohol consumption. The disease can lead to liver inflammation and fibrosis, which in turn increases the risk of developing cirrhosis and liver failure, as well as hepatocellular carcinoma. NASH has become an important medical and socioeconomic problem in recent decades due to the increasing incidence of obesity-related morbidity and metabolic syndrome. The clinical manifestations of NASH can range from asymptomatic to acute and chronic conditions requiring urgent medical attention.
History of the disease and interesting historical facts
The history of non-alcoholic steatohepatitis as a medical concept dates back to the late 20th century, when it began to be studied in more detail. In the 1980s, doctors noticed a link between obesity and liver disease, which raised new questions for the medical community. Initially, the condition was classified as “fatty liver,” but later a clinical spectrum began to be noted that went beyond simple fatty liver contamination. In 1999, the term “non-alcoholic steatohepatitis” was officially introduced, which made it possible to distinguish this condition as a separate nosology. Interestingly, similar manifestations were previously observed in people with diabetes, but it soon became clear that there are other factors that contribute to the development of the disease. Scientific research in the 2000s conducted an in-depth analysis of the pathogenesis of NASH, which made it possible to establish links between this disease and various metabolic disorders.
Epidemiology
The epidemiology of NASH shows an increasing trend of the disease spreading worldwide. According to global studies, it is difficult to identify exact figures, however, some studies indicate that the prevalence of NASH in the population ranges from 20% to 30% in developed countries. In people with obesity and type 2 diabetes, this prevalence can reach 70-90%. It is important to note that the disease affects not only the adult population, but also children, which has become one of the alarming trends of recent years. A publication by the World Health Organization (WHO) also suggested that the number of NASH cases will increase due to the global epidemic of obesity and inactive lifestyle.
Genetic predisposition to this disease
There is evidence that genetic predisposition plays a significant role in the development of non-alcoholic steatohepatitis. Studies have shown that certain genetic markers may increase the likelihood of developing NASH. Specific mutations, such as polymorphisms in lipid shunting genes such as PNPLA3, TM6SF2, and GCKR, are associated with fat accumulation in the liver. The PNPLA3 gene, which codes for lipase, is associated with more severe forms of steatohepatitis, increasing the risk of fibrosis. Research shows that carriers of risk alleles have a significantly increased risk of developing chronic inflammation and fibrosis.
Risk factors for the development of this disease
Risk factors for non-alcoholic steatohepatitis are varied and include both individual characteristics and behavioral aspects. Among the most significant factors are:
- Obesity, especially abdominal obesity, which significantly increases the risk of NASH.
- Metabolic syndrome, including insulin resistance, dyslipidemia and hypertension.
- Type 2 diabetes mellitus, which is too often associated with NASH.
- Sedentary lifestyle and lack of physical activity.
- Gender: Postmenopausal women have a higher risk due to severe metabolic changes.
- Certain medications and chemicals (such as statins or drugs used to treat tuberculosis).
- Nutritional deficiencies and excess unsaturated fats in the diet.
Diagnosis of this disease
Diagnosis of non-alcoholic steatohepatitis involves a comprehensive approach that includes both clinical and instrumental research methods. The main symptoms include:
- Fatigue and general weakness.
- Pain in the right hypochondrium.
- Changes in appetite and weight.
- Jaundice (in rare cases).
- Enlargement of the liver, which can be determined by palpation.
Laboratory tests typically include:
- A comprehensive biochemical blood test to detect elevated transaminases.
- Research for the presence of hepatitis viruses.
- Assessment of lipid and glucose levels.
Radiological imaging such as ultrasound, CT or MRI can help in identifying fatty liver. Liver biopsy is the gold standard for accurate diagnosis and assessment of inflammation and fibrosis. Differential diagnosis should exclude other causes of steatosis such as alcoholic hepatitis and viral hepatitis.
Treatment
Treatment of non-alcoholic steatohepatitis is based on the stage of the disease and can be both non-drug and drug-based. General recommendations include:
- Lifestyle modifications: weight loss, diet and increased physical activity.
- Management of comorbidities such as diabetes and hyperlipidemia.
Pharmacological treatment may include:
- Insulin sensitizers (eg, metformin) to improve carbohydrate metabolism.
- Lipid-lowering drugs (statins).
- Drugs aimed at reducing inflammation in the liver (eg, vitamin E).
In severe cases where there is significant liver damage, surgery, including liver transplantation, may be required. New approaches include the use of probiotics and antioxidants, which are also being investigated for their effects on NASH.
List of medications used to treat this disease
There are different groups of drugs used to treat NASH. They include:
- Metformin.
- Pioglitazone.
- Vitamin E.
- Statins.
- B vitamins.
- Racetam.
- Medicines based on omega-3 fatty acids.
- Antioxidants (eg beta-carotene).
Disease monitoring
Monitoring of patients with non-alcoholic steatohepatitis includes regular clinical and laboratory examinations to assess the dynamics of the liver condition. The main control stages are:
- Regular blood tests to monitor liver function.
- Clinical examinations for signs of deterioration.
- Instrumental examinations as necessary (ultrasound, CT).
The prognosis of the disease largely depends on the degree of fibrosis and the presence of metabolic syndrome. Complications such as cirrhosis and liver cancer are serious consequences and, if left untreated, can significantly worsen the quality of life and prognosis.
Age-related features of the disease
Nonalcoholic steatohepatitis can manifest itself in different age groups, but its current course varies. In children and adolescents, the disease is often associated with obesity and metabolic disorders, and is aggravated by poor diet and lack of physical activity. In adults, NASH is most often diagnosed in middle age, especially in overweight men. In older people, the disease can manifest itself more aggressively due to concomitant pathology and weakness of metabolic processes.
Questions and Answers
-
What are the main symptoms of nonalcoholic steatohepatitis?
The main symptoms include fatigue, pain in the right hypochondrium, jaundice, changes in appetite and weight, and an enlarged liver. -
How is NASH treated?
Treatment includes lifestyle modifications, drug therapy, and in severe cases, surgery may be required. -
Who is most at risk for developing NASH?
People at greatest risk for developing NASH are overweight, have metabolic syndrome, and have type 2 diabetes. -
How is non-alcoholic steatohepatitis diagnosed?
Diagnosis is based on clinical manifestations, laboratory tests and instrumental studies such as ultrasound and liver biopsy. -
Does age affect the course of the disease?
Yes, the course of NASH can vary depending on age; in children, the disease is often associated with obesity, while in older people it can develop more aggressively.
